Ask The Expert
Management of Relapsed Multiple Myeloma after Autologous Stem Cell Transplant

https://doi.org/10.1016/j.bbmt.2014.12.026Get rights and content
Under a Creative Commons license
open archive

Abstract

Autologous stem cell transplantation (ASCT) remains a standard of care for multiple myeloma patients who are eligible to receive high-dose therapy, recognizing that the optimal timing and integration of this approach is now under study in a number of randomized trials. Despite the improved response rates with induction therapy consisting of immunomodulatory drugs and/or proteasome inhibitors, as well as the increasing use of post-ASCT maintenance therapy, most myeloma patients relapse and die of their disease. Here we discuss the options for managing post-ASCT relapse, including the role of various salvage regimens in the setting of relapsed and refractory myeloma, salvage ASCT, and salvage allogeneic SCT.

Key Words

Multiple myeloma salvage autologous stem cell transplant
Salvage allogenic stem cell transplant
Monoclonal antibody
Relapsed/refractory

Cited by (0)

Financial disclosure: See Acknowledgments on page 797.